|
Jul 21
|
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
|
|
Jul 21
|
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
|
|
Jul 19
|
Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month
|
|
Jul 17
|
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts
|
|
Jul 17
|
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
|
|
Jul 16
|
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
|
|
Jul 3
|
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
|
|
Jul 3
|
MS initiates coverage on AI Biotechs, flags key pipeline catalysts
|
|
Jun 30
|
MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy
|
|
Jun 28
|
Why This Wildcard Stock Could Be a Future Star
|
|
Jun 27
|
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jun 25
|
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
|
|
Jun 16
|
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
|
|
Jun 11
|
Insmed surges on lung drug data; Recursion cuts staff
|
|
May 27
|
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
|
|
May 24
|
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales
|
|
May 5
|
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
|
|
May 5
|
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results
|
|
May 5
|
AI specialist Recursion trims pipeline in latest shakeup
|
|
May 5
|
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
|